Search Results

/MEK-targeted inhibitors. 2 , 11 In a recent study of patients with ECD neurologic involvement, a combination of anatomic MRI and metabolic imaging with FDG-PET showed a high rate of objective response to targeted therapies such as vemurafenib. 12 This report presents a

rectal examination and prostate MRI (NCT03805919). If clinical trial participation is not available, annual PSA measurement for carriers of high-risk mutations should begin at age 40 years ( Figure 2 ). Men with PSA levels greater than the median age

/L), a creatinine level of 1.9 mg/dL (range, 0.6-1.3 mg/dL), and a glomerular filtration rate (GFR) of 38 mL/min. Imaging studies, including magnetic resonance cholangiopancreatography and MRI of the liver, revealed a perihilar liver mass measuring 48.6 x

received conventional CRT with 5FU or capecitabine. All patients got MRI and endorectal ultrasound (ERUS) at baseline, after completing FOLFOX 3-months regimen and after finishing conventional CRT. Patients underwent either full-thickness local excision or

, targeted nanoparticles can provide molecular imaging functionality through site- or activity-specific localization. Iron oxide nanoparticles provide a sensitive, low-toxicity alternative to standard MRI contrast agents, such as injected gadolinium. 39

least one prior negative biopsy. 51 , 55 MRI Increasing interest is being shown in the role of multiparametric MRI in prostate cancer diagnosis. Recent evidence suggests a benefit of MRI-targeted prostate biopsy compared with standard transrectal

no significant past medical history presented with sudden onset of severe right-sided headache and emesis. MRI revealed 2 rim-enhancing lesions in the right temporal lobe. The patient underwent a gross total resection of the lesions, with surgical

tracking . J Mag Reson Imaging 2005 ; 22 : 710 – 717 . 45. Wong ET Jackson EF Hess KR . Correlation between dynamic MRI and outcome in patients with malignant gliomas . Neurology 1998 ; 50 : 777 – 781 . 46. Roberts HC Roberts

CA19-9 tumor marker response during treatment. (B) CT image from PET/CT scan before trastuzumab + lapatinib (red arrow: liver lesion, 2.4 × 1.4 cm). (C) MRI scan after 8 cycles of trastuzumab + lapatinib (red arrow: the same lesion, 0.7 × 0.9 cm

at the anterior mediastinum, liver, bone marrow, skull, and third lumber vertebra. Brain MRI revealed disease in the right orbital fossa extending to the middle cranial fossa, with no intracranial or cerebellar disease. The patient underwent fine